Pfizer is now beginning phase two of a study to determine how well a new drug works to cure coronavirus.
In total, up to 2,660 healthy and adults will participate in the randomized, double-blind, placebo-controlled study.
The goal is to see how safe and effective the drug is at stopping symptomatic COVID-19 disease.
“If we succeed, we believe this cure could stop the virus early in the process before it has the opportunity to spread through the body.
“Then we can potentially prevent symptomatic disease in those who are infected,” Pfizer’s global research manager, Mikael Dolsten, stated.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNewsInternet Explorer Channel Network